Point72 Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Point72 Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43M	Sell	2,136,940 -146,826	-6%	-$2.37M	0.06%	433
2025 Q4	$36.9M	Buy	+2,283,766	New	+$30.2M	0.04%	552
2022 Q4	–	Sell	-57,800	Closed	-$839K	–	1656
2022 Q3	$839K	Buy	+57,800	New	+$808K	﹤0.01%	1087
2019 Q4	–	Sell	-87,000	Closed	-$1.01M	–	1096
2019 Q3	$1.01M	Sell	87,000 -75,900	-47%	-$1.23M	0.01%	686
2019 Q2	$3.61M	Buy	+162,900	New	+$3.82M	0.02%	574

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Point72 Asset Management's KALV Position: Q1 2026 in Review

Point72 Asset Management reduced its KalVista Pharmaceuticals (KALV) stake by 6.4% in Q1 2026, selling an estimated $2.37M and leaving 2,136,940 shares worth $43M. The position accounts for 0.06% of the portfolio, ranked #433.

Point72 Asset Management first reported a position in KALV in Q2 2019 and has held it in 5 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Point72 Asset Management held 2,136,940 shares of KalVista Pharmaceuticals worth $43M as of Q1 2026.
Point72 Asset Management sold 146,826 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.37M.
KalVista Pharmaceuticals made up 0.06% of Point72 Asset Management's portfolio in Q1 2026, its #433 holding.
Point72 Asset Management first reported a position in KalVista Pharmaceuticals in Q2 2019 and has held it in 5 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.